Betahistine - Obecure

Drug Profile

Betahistine - Obecure

Alternative Names: Histalean; OBE 101

Latest Information Update: 18 Jul 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Obecure
  • Class Pyridines; Small molecules
  • Mechanism of Action Histamine H1 receptor agonists; Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hyperlipidaemia; Obesity; Weight gain

Most Recent Events

  • 31 Dec 2010 Obecure completes a phase I trial in healthy volunteers in Romania [NCT01168336]
  • 26 Feb 2010 National Institutes of Health completes enrolment in its Phase-I trial (NCT00459992) for Obesity in USA
  • 17 Feb 2010 Grunenthal and Obecure Pharmaceuticals enter into an extension of their original strategic supply agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top